Aristotle Capital Management Llc sold 5,068 shares as Amgen Inc (AMGN)'s stock declined 9.68%. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.11. The stock increased 1.44% or $1.17 during the last trading session, reaching $82.23.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. It has underperformed by 38.50% the S&P500.
Pdt Partners Llc decreased Gilead Sciences Inc (GILD) stake by 9.11% reported in 2017Q3 SEC filing. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% in the second quarter. The institutional investor held 75,000 shares of the packaged foods company at the end of 2017Q3, valued at $5.21M, up from 50,000 at the end of the previous reported quarter. Clearbridge Investments Llc who had been investing in Wells Fargo Co New for a number of months, seems to be bullish on the $282.30B market cap company.
The stock decreased 0.11% or $0.02 during the last trading session, reaching $18.39. About 1.45M shares traded or 8.74% up from the average. It has outperformed by 76.04% the S&P500. After $-0.05 actual earnings per share reported by Trupanion, Inc. for the previous quarter, Wall Street now forecasts -20.00% EPS growth.
Tb Alternative Assets Ltd increased A Snap Us stake by 250,200 shares to 251,800 valued at $3.66M in 2017Q3. While talking about Performance of the Stock, Gilead Sciences Inc. now has a Weekly performance of 4.03%, monthly performance percentage is 3.63 percent, Quarterly performance is 11.47 percent, 6 months performance shows a percent value of -4.75% and Yearly Performance is 18.87 percent. Therefore 70% are positive. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. (NASDAQ:GILD) earned "Outperform" rating by Credit Suisse on Wednesday, February 3.More news: A Technical Perspective on Rite Aid Corporation (RAD)
Shares of Gilead Sciences, Inc. Piper Jaffray maintained the shares of GILD in report on Tuesday, July 25 with "Buy" rating. The stock presently has a consensus rating of "Buy" and an average price target of $87.75. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. On Monday, August 28 the stock rating was maintained by BMO Capital Markets with "Hold". Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the company a "hold" rating in a research note on Wednesday, January 3rd. As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. The firm has "Buy" rating given on Friday, November 3 by Northland Capital.
Since October 2, 2017, it had 0 insider purchases, and 13 insider sales for $41.72 million activity. Financial Bank Of America Corp De owns 0.13% invested in Gilead Sciences, Inc.
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. It increased, as 96 investors sold GILD shares while 488 reduced holdings.
Investors sentiment increased to 1.03 in Q3 2017. Its down 0.15, from 0.88 in 2017Q2. It also reduced its holding in Aon Plc (NYSE:AON) by 4,265 shares in the quarter, leaving it with 11,384 shares, and cut its stake in Resmed Inc (NYSE:RMD). Capital International Investors raised its stake in shares of Gilead Sciences by 86.6% during the 3rd quarter. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Dowling Yahnke Ltd holds 0.11% or 17,720 shares in its portfolio. Patten & Patten Tn has invested 0.02% in Gilead Sciences, Inc.
Among 39 analysts covering Wells Fargo & Company (NYSE:WFC), 15 have Buy rating, 8 Sell and 16 Hold. (NASDAQ:GILD). Prelude Mngmt Ltd owns 0.07% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Patten Gru holds 0.02% or 50,032 shares in its portfolio. Welch Investments LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth about $108,000. On Friday, February 9 the insider WILSON GAYLE E sold $4.68M.More news: 'No-deal Brexit' annual cost could reach £58bn for UK, EU companies
United Asset Strategies Inc, which manages about $731.00M and $176.37M US Long portfolio, decreased its stake in Boeing Co (NYSE:BA) by 1,629 shares to 2,092 shares, valued at $532,000 in 2017Q3, according to the filing. 193,571 were reported by Cambridge Invest Research Advsrs. Arrowstreet Capital Lp accumulated 24,280 shares or 0.01% of the stock. Legacy Cap Prns Incorporated accumulated 9,398 shares. They expect $-0.04 earnings per share, up 20.00% or $0.01 from last year's $-0.05 per share. First Quadrant Limited Partnership Ca holds 0.31% or 139,504 shares. Fruth Investment accumulated 12,483 shares. Advisory Services Network Ltd Limited Liability Company reported 0.17% stake. Bridges Inv Counsel has invested 0.38% in Gilead Sciences, Inc. Maxim Group maintained Gilead Sciences, Inc. The Switzerland-based Bb Biotech Ag has invested 6.22% in Gilead Sciences, Inc. (NASDAQ:GILD) or 100,000 shares. (NASDAQ:GILD) rating on Wednesday, February 3. The firm earned "Hold" rating on Friday, April 29 by Maxim Group. As per Friday, January 26, the company rating was upgraded by Jefferies.
Since December 14, 2017, it had 5 insider buys, and 1 insider sale for $277,713 activity. The rating was maintained by Cowen & Co on Tuesday, July 25 with "Buy". BMO Capital Markets has "Hold" rating and $88.0 target. (NASDAQ:GILD) for 10.39M shares. Beach Counsel Pa, Pennsylvania-based fund reported 14,656 shares. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company's stock valued at $446,197,000 after purchasing an additional 2,524,657 shares during the period.
Muhlenkamp & Co Inc, which manages about $560.67M and $317.58M US Long portfolio, decreased its stake in Teva Pharmaceutcl Inds Adr (Call) (NYSE:TEVA) by 93,505 shares to 13,000 shares, valued at $229,000 in 2017Q3, according to the filing. The company was upgraded on Tuesday, December 6 by Morgan Stanley. Essex Inv Management Lc stated it has 0.4% of its portfolio in Oclaro, Inc. Compton Capital Mngmt Ri, Rhode Island-based fund reported 62,360 shares. Endurance Wealth Mngmt accumulated 26,160 shares.
Investors sentiment increased to 0.86 in 2017 Q3. Following the sale, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. Cypress Asset Mgmt Tx stated it has 21,125 shares. GILD's profit will be $2.08 billion for 12.70 P/E if the $1.59 EPS becomes a reality. (NASDAQ:GILD) for 670 shares. 601.66 million shares or 1.15% less from 608.67 million shares in 2017Q2 were reported. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Sumitomo Mitsui Asset Management has invested 0.1% of its portfolio in Ecolab Inc. Its down 0.02, from 0.92 in 2017Q2.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.More news: International Business Machines Corp. (IBM) Position Trimmed by BTIM Corp